SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)
Understand this study
Who could participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Orbetello and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 85
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Italy
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03210480
- Official title
Show the full official title
Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment.
Recruitment & locations
Orbetello · Bergamo · Genova
3 more locations
- Pisa
- Roma
- Siena
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Aziende Chimiche Riunite Angelini Francesco S.p.A.
Does this study involve medication?
Yes. The study involves medication, including Lithium sulphate prolonged-release 660 mg and Lithium carbonate immediate-release 150 mg and 300 mg.
Who can participate?
This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
